Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/6/2024 | $10.00 | Buy | ROTH MKM |
1/5/2022 | $20.00 | Buy | EF Hutton |
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
Longeveron has licensed issued US Patent 12,168,028 B2, entitled "Methods for obtaining cardiomyogenic precursor cells" from the University of MiamiNew patent protects a method to derive GHRH-Receptor+ cardiomyogenic cells from pluripotent stem cells (PSCs)New technology substantially advances Longeveron's repertoire of stem cell therapy technologiesOpportunity to expand pipeline in cardiovascular, rare and pediatric disease areas MIAMI, July 21, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric, and chronic aging-related conditions, today announced that i
Accepted IND application allows for development program to move directly to a Phase 2 pivotal registration clinical trialPhase 2 clinical trial initiation anticipated in first half of 2026Pediatric cardiomyopathies affect at least 100,000 children worldwideEffective treatment options are limited, with nearly 40% of children with DCM requiring a heart transplant or dying within two years of diagnosis MIAMI, July 08, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that the U.S. Food and Drug Administration (FDA) has ap
Mr. Powell to oversee Longeveron's partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In this role, he will lead the Company's overall business strategy, Alzheimer's disease program partnering efforts, and international strategy for the hypoplastic left heart syndrome (HLHS) program. "We are delighted to have Than join Longeveron at this transformational time in the Company's
8-K - Longeveron Inc. (0001721484) (Filer)
S-8 - Longeveron Inc. (0001721484) (Filer)
8-K - Longeveron Inc. (0001721484) (Filer)
ROTH MKM initiated coverage of Longeveron with a rating of Buy and set a new price target of $10.00
EF Hutton initiated coverage of Longeveron with a rating of Buy and set a new price target of $20.00
Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to complete enrollment in the second quarter of 2025Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II is successfulResults from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer's disease were published in Nature MedicinePositive FDA meeting regarding development pathway for laromestrocel in mild Alzheimer's disease; single, pivotal Phase 2/3 adaptive design clinica
MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report first quarter 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference Call Number: 1.877.407.0789 Conference ID: 13752361 Call meTM Feature: Click HereWebcast: Click Here An archived replay of the webcast will be available o
Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more than 90% enrollment and is expected to complete enrollment in the second quarter of 2025Lomecel-B™ Biological License Application (BLA) submission for full traditional approval anticipated in 2026, if ELPIS II is successfulFDA meeting anticipated late in first quarter of 2025 to discuss possible development paths for Lomecel-B™ in mild Alzheimer's diseaseWHO International Nonproprietary Names (INN) Expert Committee approved "laromestrocel" for the non-proprietary name of Lomecel-B™Total Revenue
Mr. Powell to oversee Longeveron's partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In this role, he will lead the Company's overall business strategy, Alzheimer's disease program partnering efforts, and international strategy for the hypoplastic left heart syndrome (HLHS) program. "We are delighted to have Than join Longeveron at this transformational time in the Company's
MIAMI, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Devin Blass as Chief Technology Officer (CTO) and Senior Vice President of Chemistry, Manufacturing, and Controls (CMC), effective December 2, 2024. In this role, he will lead the Company's technological and manufacturing strategies. "We are delighted to have Devin join Longeveron at this transformational time in the Company's evolution," said Wa'el Hashad, Chief Executive Officer at Longeveron. "This appointment reinforces Longevero
MIAMI, July 09, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (HLHS) and Alzheimer's disease, today announced that Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors at the Company's recent Annual Meeting of Stockholders. "I am delighted to welcome Neha, with her tremendous healthcare industry experience, to the Board of Directors," said Joshua Hare, Co-founder, Chief Science Officer and Chairman of the Board at Longeveron. "Her exte
SC 13G/A - Longeveron Inc. (0001721484) (Subject)
SC 13G - Longeveron Inc. (0001721484) (Subject)
SC 13G - Longeveron Inc. (0001721484) (Subject)